Company Dossier · Health Care
Medpace
- Russell 1000
- MidCap 400
What Medpace is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $2.78 billion, up 25% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.71 billion, up 22% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.05 billion, up 67% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.92 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 23, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 10, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $178 million on the open market.SEC Form 4
- 696 institutional managers reported a position at June 30, 2026 (−37 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 5 (14 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Medpace yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Medpace, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralUBS Initiates Coverage of Medpace (MEDP) with Neutral Rating and $673 Price Target
gurufocus.com · via Marketaux · Sep 30, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Aug 25, 2026Trademark
- Jun 4, 20268-KDirector or officer changeItem 5.02
- May 19, 20268-KShareholder vote resultsItem 5.07
- Apr 22, 20268-KDirector or officer changeItem 5.02
- Feb 10, 202610-KAnnual report (10-K)0 risk factors added, 0 removed
- Jul 21, 20258-KMaterial agreement signedItem 1.01
- May 16, 20258-KDirector or officer changeItem 5.02
- May 16, 20258-KShareholder vote resultsItem 5.07
- Apr 21, 20258-KMaterial agreement signedItem 1.01
- Mar 31, 20258-KMaterial agreement signedItem 1.01
- Feb 11, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 13, 202410-KAnnual report (10-K)2 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Natera NTRA | $2.7B | $0.1B | Jun 30, 2026 |
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Hims & Hers Health HIMS | $2.6B | $0.1B | Jun 30, 2026 |
| Royalty Pharma RPRX | $2.5B | — | Jun 30, 2026 |
| Insulet Corporation PODD | $3.0B | $0.3B | Jun 30, 2026 |